IRLAB publishes prospectus relating to the rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL PURSUANT TO APPLICABLE RULES OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The prospectus relating to IRLAB Therapeutics AB’s (publ) (“IRLAB” or the “Company”) previously communicated rights issue of approximately SEK 145 million (the “Rights Issue”) was approved and registered by the Swedish Financial Supervisory Authority today on 7